Changes in cellular proliferation and plasma products are associated with liver failure

Table 1 Clinical characteristics of the studied population n (%)

	Acute liver failure (n = 16)	Acute hepatitis (n = 46)	Healthy control (n = 22)
Age (yr)
Mean ± SD	24.88 ± 21.52	21.21 ± 10.32	24.64 ± 8.79
25%, 75%	9.25, 49	9.1, 29.75	15.2, 47
Gender
Male	6 (37.50)	25 (54.34)	9 (40.9)
Diagnosis
Hepatitis A	11 (68.75)	38 (82.60)	0
Drug toxicity	2 (12.50)	2 (4.34)	0
Indeterminate	3 (18.75)	6 (13.04)	0
Liver enzymes
AST (UI/L)	1095.5 ± 1460	344.5 ± 444.9	21.68 ± 4.87
ALT (UI/L)	806.12 ± 639.11	517.90 ± 884.30	14.36 ± 4.50
Total bilirubin (mg/dL)	21.47 ± 10.48	10.01 ± 6.88	0.85 ± 0.09
Coma grade
0-I	3 (18.75)	0	0
II-IV	13 (81.25)	0	0
Coagulopathy
INR (mean ± SD)	4.88 ± 0.99	1.16 ± 0.04	0.98 ± 0.06
Outcome
Survived	6 (46.15)	46 (100.00)	22 (100)
Died	10 (53.84)	0	0

INR: International normalized ratio; SD: Standard deviation; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.